

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Follistatin-like 1 (FSTL1)	<p>Mouse and cell culture studies suggest inhibiting FSTL1 could help prevent cancer metastasis to the bone. In mouse and human cancer cell lines, small interfering RNA knockdown of <i>FSTL1</i> decreased invasiveness and expression of bone metastasis-associated factors compared with no knockdown. In mouse xenograft models of melanoma, siRNA against <i>Fstl1</i> decreased tumor growth, metastasis to the bone and survival compared with control siRNA. Next steps include developing FSTL1 inhibitors and conducting studies in patient samples to determine whether there is a correlation between elevated FSTL1 levels and bone metastasis.</p> <p><i>SciBX</i> 6(37); doi:10.1038/scibx.2013.1024 Published online Sept. 26, 2013</p>	<p>Patent application filed; available for licensing from the Keio University School of Medicine Contact: Koji Nakamoto, Keio University School of Medicine, Tokyo, Japan e-mail: koji.nakamoto@adst.keio.ac.jp</p>	<p>Kudo-Saito, C. <i>et al. Cancer Res.</i>; published online Aug. 21, 2013; doi:10.1158/0008-5472.CAN-13-1364 Contact: Chie Kudo-Saito, Keio University School of Medicine, Tokyo, Japan e-mail: kudoc@a3.keio.jp</p>